FrancophonIA/ELRC3.0 huggingface dataset:
English: In order to reduce the risk of developing osteonecrosis of the jaw, there are some precautions you should take.
Slovenian: Da bi zmanjšali tveganje za razvoj osteonekroze čeljusti, je treba upoštevati nekaj previdnostnih ukrepov.
English: It is important to try and prevent ONJ developing as it is a painful condition that can be difficult to treat.
Slovenian: Pomembno je, da poskušamo preprečiti razvoj osteonekroze čeljusti, saj je to zelo boleče stanje, ki ga je večkrat težko zdraviti.
English: - After opening the bottle, the product should be used immediately in order to avoid microbial contamination.
Slovenian: - Po odpiranju steklenice je treba zdravilo uporabiti takoj, da ne bi prišlo do kontaminacije z mikroorganizmi.
English: - Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. - The unopened bottle does not require any special storage conditions.
Slovenian: - Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in steklenici poleg oznake EXP. - Za shranjevanje neodprte steklenice niso potrebna posebna navodila.
English: The incidence of post-dose symptoms occurring within the first three days after administration of Aclasta can be reduced with the administration of paracetamol or ibuprofen shortly following Aclasta administration.
Slovenian: Incidenco simptomov po odmerjanju, ki nastopijo v prvih treh dneh po aplikaciji zdravila Aclasta, je mogoče znižati z jemanjem paracetamola ali ibuprofena kmalu po aplikaciji zdravila Aclasta.
English: What you need to know before you are given Aclasta
Slovenian: Kaj morate vedeti, preden vam dajo zdravilo Aclasta
English: • Physician educational material
Slovenian: • Izobraževalno gradivo za zdravnika
English: Aclasta should not be used in children and adolescents below 18 years of age.
Slovenian: Zdravila Aclasta se ne sme uporabljati pri otrocih in mladostnikih, ki so stari manj kot 18 let.
English: After opening: 24 hours at 2°C - 8°C
Slovenian: Po odpiranju: 24 ur pri 2°C - 8°C.
English: The physician educational material should contain the following key elements:
Slovenian: Izobraževalno gradivo za zdravnika mora vsebovati naslednje ključne sestavine:
English: INFORMATION FOR THE HEALTHCARE PROFESSIONAL
Slovenian: INFORMACIJE ZA ZDRAVSTVENO OSEBJE
English: Teratogenicity was observed in rats at doses ≥ 0.2 mg/kg and was manifested by external, visceral and skeletal malformations.
Slovenian: Teratogenost so ugotovili pri podganah v odmerkih ≥0,2 mg/kg, ki se je kazala v obliki zunanjih, visceralnih in skeletnih malformacij.
English: Therefore, interactions resulting from displacement of highly protein-bound medicinal products are unlikely.
Slovenian: Zato interakcije, ki se kažejo kot izrivanje zdravil pretežno vezanih na beljakovine, niso verjetne.
English: In a large clinical trial in 7,736 patients, osteonecrosis of the jaw has been reported in one patient treated with Aclasta and one patient treated with placebo.
Slovenian: V obsežnem kliničnem preskušanju s 7.736 bolniki so o osteonekrozi čeljusti poročali pri enem bolniku, ki je prejemal zdravilo Aclasta, in pri enem bolniku, ki je prejemal placebo.
English: This is especially important for the elderly (≥65 years)and for patients receiving diuretic therapy.
Slovenian: To je posebno pomembno za starejše (stare 65 let ali več) in za bolnike, ki jemljejo tudi diuretike.
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C - 8°C.
Slovenian: Če uporabnik raztopine ne uporabi takoj, je za čas in pogoje shranjevanja do uporabe odgovoren sam. Čas do uporabe naj praviloma ne presega 24 ur pri temperaturi 2 °C8 °C.
English: What Aclasta is and what it is used for What you need to know before you are given Aclasta How Aclasta is given
Slovenian: Kaj je zdravilo Aclasta in za kaj ga uporabljamo Kaj morate vedeti, preden vam dajo zdravilo Aclasta Kako se daje zdravilo Aclasta Možni neželeni učinki
English: No new vertebral fractures were observed in the zoledronic acid group as compared to two new fractures in the placebo group.
Slovenian: V skupini z zoledronsko kislino niso opažali novih zlomov vretenc v primerjavi z dvema novima zlomoma v skupini s placebom.
English: Effect on all clinical fractures
Slovenian: Učinek na vse klinične zlome
English: It is important for your doctor to know all the medicines you are taking, especially if you are taking any medicines known to be harmful to your kidneys (e.g. aminoglycosides) or diuretics (“waterpills”) that may cause dehydration.
Slovenian: Pomembno je, da vaš zdravnik ve, katera zdravila jemljete, zlasti če jemljete zdravila, za katera je znano, da lahko škodujejo ledvicam (na primer aminoglikozide) ali diuretike ("zdravila za odvajanje vode"), ki lahko povzročajo dehidracijo.
English: Thus these results precluded determining a definitive effect of Aclasta on fertility in humans.
Slovenian: Na podlagi teh rezultatov ni mogoče ugotavljati dejanskega vpliva zdravila Aclasta na plodnost pri ljudeh.
English: The majority of these reactions occur within the first three days following Aclasta administration.
Slovenian: Večina teh učinkov je nastopila v prvih treh dneh po aplikaciji zdravila Aclasta.
English: Aclasta demonstrated a consistent effect over 3 years, resulting in a 41% reduction in the risk of hip fractures (95% CI, 17% to 58%).
Slovenian: Zdravilo Aclasta je pokazalo stalen učinek v obdobju 3 let, kar je omogočilo 41-odstotno znižanje tveganja za zlom kolkov (95 % IZ: 17 % do 58 %).
English: For the treatment of Paget's disease, Aclasta should be prescribed only by physicians with experience in the treatment of Paget's disease of the bone.
Slovenian: Za zdravljenje Pagetove bolezni smejo zdravilo Aclasta predpisovati samo zdravniki, ki imajo izkušnje z zdravljenjem Pagetove bolezni kosti.
English: If you missed a dose of Aclasta Contact your doctor or hospital as soon as possible to re-schedule your appointment.
Slovenian: Če ste izpustili odmerek zdravila Aclasta Čimprej pokličite zdravnika oziroma v bolnišnico, da se dogovorite za nov datum.
English: The study was not powered to show a reduction in clinical fractures in men; the incidence of clinical fractures was 7.5% in men treated with Aclasta versus 8.7% for placebo.
Slovenian: S študijo ni bilo mogoče pokazati zmanjšanja obsega kliničnih zlomov pri moških; incidenca kliničnih zlomov je bila pri moških, zdravljenih z zdravilom Aclasta, 7,5 % v primerjavi z 8,7 % pri uporabi placeba.
English: Driving and using machines If you feel dizzy while taking Aclasta, do not drive or use machines until you feel better.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Če ste v obdobju zdravljenja z zdravilom Aclasta omotični, ne vozite in ne upravljajte strojev, dokler se vaše počutje ne izboljša.
English: CARTON FOR INTERMEDIATE PACK (WITHOUT BLUE BOX)
Slovenian: ŠKATLA ZA VMESNO PAKIRANJE (BREZ PODATKOV V t.i. MODREM OKENCU)
English: The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of Aclasta.
Slovenian: Večina neželenih učinkov, kot so vročina z mrzlico, bolečine v mišicah in sklepih in glavobol, nastopi v prvih treh dneh po odmerku zdravila Aclasta.
English: Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.
Slovenian: Podaljšanje časa infundiranja s 5 na 15 minut je povzročilo 30-odstotno znižanje koncentracije zoledronske kisline ob koncu infundiranja, ni pa vplivalo na površino pod krivuljo plazemske koncentracije v odvisnosti od časa.
English: The recommended dose is a single intravenous infusion of 5 mg Aclasta.
Slovenian: Priporočeni odmerek je ena intravenska infuzija s 5 mg zdravila Aclasta.
English: In both women and men, Aclasta strengthens the bone and therefore makes it less likely to break.
Slovenian: Tako pri ženskah kot pri moških zdravilo Aclasta okrepi kosti in tako zmanjša verjetnost zlomov.
English: Due to the rapid onset of effect of zoledronic acid on bone turnover, transient hypocalcaemia, sometimes symptomatic, may develop and is usually maximal within the first 10 days after infusion of Aclasta (see section 4.8).
Slovenian: Zaradi hitrega začetka delovanja zoledronske kisline na pregradnjo kosti se utegne razviti prehodna hipokalciemija, ki je včasih simptomatska in ki je navadno najbolj izražena v prvih 10 dneh po infuziji zdravila Aclasta (glejte poglavje 4.8).
English: It is supplied in packs containing one bottle as unit pack, or in multipacks comprising five packs, each containing one bottle.
Slovenian: Na voljo je v škatlah, ki vsebujejo eno steklenico kot posamično pakiranje ali v skupnem pakiranju s petimi škatlami, ki vsebujejo po eno steklenico.
English: Justification for not including braille accepted.
Slovenian: Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
English: Your doctor may ask you to undergo a dental examination before you start treatment with Aclasta.
Slovenian: Zdravnik vas bo verjetno prosil, da pred začetkom zdravljenja z zdravilom Aclasta opravite zobozdravstveni pregled.
English: For information on the infusion of Aclasta, see section 6.6.
Slovenian: Za informacije o infundiranju zdravila Aclasta glejte poglavje 6.6.
English: After 6 months, Aclasta showed 96% (169/176) and 89% (156/176) response and serum alkaline phosphatase (SAP) normalisation rates compared to 74% (127/171) and 58% (99/171) for risedronate (all p<0.001).
Slovenian: Po 6 mesecih je zdravilo Aclasta pokazalo 96-odstotno (169/176) oziroma 89-odstotno odzivnost (156/176) oziroma pogostost normalizacije koncentracije serumske alkalne fosfataze (SAP) v primerjavi s 74 % (127/171) oziroma 58 % (99/171) pri risedronatu (v vseh primerih p <0,001).
English: Multipack: 5 bottles, each bottle of 100 ml.
Slovenian: Skupno pakiranje:5 steklenic po 100 ml.
English: Repeat dosing did not lead to further reduction of bone turnover markers.
Slovenian: Ponovljeno odmerjanje ni povzročalo nadaljnega zniževanja koncentracij označevalcev pregradnje kosti.
English: Clear and colourless solution.
Slovenian: Bistra in brezbarvna raztopina.
English: The study was planned to include 92 patients, however only 34 patients were enrolled and randomised to receive either a twice-yearly 0.05 mg/kg (max. 5 mg) intravenous zoledronic acid infusion or placebo for one year.
Slovenian: Načrtovano je bilo, da bo v študijo vključenih 92 bolnikov, vendar so vključili in randomizirali samo 34 bolnikov, in sicer tako, da so eno leto prejemali bodisi zoledronsko kislino 0,05 mg/kg (največ 5 mg) z intravensko infuzijo dvakrat na leto ali placebo.
English: In case you recently broke your hip, it is recommended that Aclasta is administered two or more weeks after your hip repair surgery.
Slovenian: Če ste si pred kratkim zlomili kolk, je priporočljivo, da dobite zdravilo Aclasta dva ali več tednov po operativnem zdravljenju kolka.
English: Small observed increases in AUC(0-24hr), by about 30% to 40% in mild to moderate renal impairment, compared to a patient with normal renal function, and lack of accumulation of drug with multiple doses irrespective of renal function, suggest that dose adjustments of zoledronic acid in mild (Clcr = 50-80 ml/min) and moderate renal impairment down to a creatinine clearance of 35 ml/min are not necessary.
Slovenian: Majhno zvečanje AUC(0-24hr) za okrog 30 do 40 %, ki so ga opazili pri bolnikih z blago do zmerno ledvično okvaro v primerjavi z bolniki z normalnim ledvičnim delovanjem, in odsotnost kopičenja zdravila ob večkratnih odmerkih, ne glede na ledvično delovanje, kažeta, da prilagajanje odmerka zoledronske kisline pri blagi (Clcr = 50 do 80 ml/min) in zmerni ledvični okvari z znižanim očistkom kreatinina do 35 ml/min ni potrebno.
English: The most commonly reported adverse reactions after infusion of zoledronic acid were arthralgia (28%), pyrexia (22%), vomiting (22%), headache (22%), nausea (17%), myalgia (17%), pain (17%), diarrhoea (11%) and hypocalcaemia (11%).
Slovenian: Neželeni učinki po prejemu infuzije zoledronske kisline, o katerih so najbolj pogosto poročali, so bili artralgija (28 %), zvišana telesna temperatura (22 %), bruhanje (22 %), glavobol (22 %), navzea (17 %), mialgija (17 %), bolečine (17 %), driska (11 %) in hipokalciemija (11 %).
English: Uncommon Hypertension, flushing Not known** Hypotension (some of the patients had underlying risk factors)
Slovenian: Žilne bolezni občasni hipertenzija, navali rdečice neznana** hipotenzija (pri nekaterih od teh bolnikov so bili že prej prisotni dejavniki tveganja)
English: 1 bottle of 100 ml
Slovenian: 1 steklenica s 100 ml
English: Pre-existing hypocalcaemia must be treated by adequate intake of calcium and vitamin D before initiating therapy with Aclasta (see section 4.3).
Slovenian: Že obstoječo hipokalciemijo je treba zdraviti z zadostnim vnosom kalcija in vitamina D še pred uvedbo zdravljenja z zdravilom Aclasta (glejte poglavje 4.3).
English: For the treatment of post-menopausal osteoporosis, osteoporosis in men and the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy, the recommended dose is a single intravenous infusion of 5 mg Aclasta administered once a year.
Slovenian: Za zdravljenje postmenopavzalne osteoporoze, osteoporoze pri moških in osteoporoze zaradi dolgotrajnega zdravljenja s sistemskimi glukokortikoidi je priporočeni odmerek ena intravenska infuzija s 5 mg zdravila Aclasta enkrat na leto.
English: The use of Aclasta in patients with severe renal impairment (creatinine clearance < 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Slovenian: Uporaba zdravila Aclasta pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 35 ml/min) je kontraindicirana zaradi povečanega tveganja za odpoved ledvic pri tej populaciji.
English: Adverse reactions in Table 1 are listed according to MedDRA system organ class and frequency category.
Slovenian: Neželeni učinki v preglednici 1 so navedeni glede na organski sitem po MedDRA klasifikaciji in glede na kategorijo pogostnosti.
English: The incidence of delayed hip fracture healing was comparable between Aclasta (34 [3.2%]) and placebo (29 [2.7%]).
Slovenian: Incidenca zakasnitve celjenja zloma kolka je bila primerljiva med skupinama z zdravilom Aclasta (34 [3,2 %]) oziroma s placebom (29 [2,7 %]).
English: Zoledronic acid is not highly bound to plasma proteins (approximately 43-55% bound) and interactions resulting from displacement of highly protein-bound medicinal products are therefore unlikely.
Slovenian: Zoledronska kislina se ne veže v veliki meri na beljakovine plazme (vezana je približno v 43-55 %), zato interakcije, ki se kažejo kot izrinjanje zdravil pretežno vezanih na beljakovine, niso verjetne.
English: Children and adolescents Aclasta is not recommended for anyone under 18 years of age.
Slovenian: Otroci in mladostniki Uporaba zdravila Aclasta ni priporočljiva pri mlajših od 18 let.
English: Concomitant osteoporosis therapy included: calcitonin, raloxifene, tamoxifen, hormone replacement therapy, tibolone; but excluded other bisphosphonates.
Slovenian: Sočasno zdravljenje osteoporoze je vključevalo: kalcitonin, raloksifen, tamoksifen, hormonsko nadomestno zdravljenje, tibolon; uporaba drugih difosfonatov pri tem ni bila dovoljena.
English: All cause mortality was 10% (101 patients) in the Aclasta-treated group compared to 13% (141 patients) in the placebo group.
Slovenian: Umrljivost iz kateregakoli vzroka je bila 10 % v skupini, zdravljeni z zdravilom Aclasta (101 bolnik), v primerjavi s 13 % v skupini s placebom (141 bolnikov).
English: It belongs to a group of medicines called bisphosphonates and is used to treat post-menopausal women and adult men with osteoporosis or osteoporosis caused by treatment with corticosteroids used to treat inflammation, and Paget's disease of the bone in adults.
Slovenian: Pripada skupini zdravil, ki se imenujejo difosfonati in jih uporabljamo za zdravljenje postmenopavzalnih žensk in odraslih moških z osteoporozo ali z osteoporozo zaradi zdravljenja s kortikosteroidi za zmanjševanje vnetja in s Pagetovo boleznijo kosti pri odraslih.
English: Zoledronic acid has been associated with renal impairment manifested as deterioration in renal function (i.e. increased serum creatinine) and in rare cases acute renal failure.
Slovenian: Zoledronsko kislino povezujejo z okvaro ledvic ki se kaže kot poslabšanje delovanja ledvic (zvišanje koncentracije kreatinina v serumu) in v redkih primerih z akutno odpovedjo ledvic.
English: • Need for adequate calcium and vitamin D supplementation, appropriate physical activity,
Slovenian: • potrebnost zadostnega nadomeščanja kalcija in vitamina D, ustrezne telesne dejavnosti in zdrave prehrane ter odsotnosti kajenja,
English: - Hypersensitivity to the active substance, to any bisphosphonates or to any of the excipients listed in section 6.1.
Slovenian: - Preobčutljivost na učinkovino, katerega od difosfonatov ali katero koli pomožno snov, navedeno v poglavju 6.1.
English: While on treatment, invasive dental procedures should be performed with caution and avoided in close proximity to zoledronic acid treatment.
Slovenian: Med zdravljenjem je potrebna previdnost pri izvajanju invazivnih zobozdravstvenih posegov, povsem pa se jim je treba izogniti v času blizu termina odmerjanja zoledronske kisline.
English: - Aclasta 5 mg solution for infusion is ready for use.
Slovenian: - Zdravilo Aclasta 5 mg raztopina za infundiranje je že pripravljeno za uporabo.
English: Re-treatment of Paget's disease: After initial treatment with Aclasta in Paget's disease, an extended remission period is observed in responding patients.
Slovenian: Ponovno zdravljenje Pagetove bolezni: Po začetnem zdravljenju Pagetove bolezni z zdravilom Aclasta opažajo pri bolnikih, ki se odzovejo na zdravljenje, obdobje dolgotrajne remisije.
English: In the osteoporosis trials (PFT, HORIZON - Recurrent Fracture Trial [RFT]) the pooled atrial fibrillation incidences were comparable between Aclasta (2.6%) and placebo (2.1%).
Slovenian: V študijah osteoporoze (v PFT, v študiji HORIZON - študiji ponovnih zlomov (Recurrent Fracture Trial [RFT]) sta bili združeni incidenci atrijske fibrilacije primerljivi med zdravilom Aclasta (2,6 %) in placebom (2,1 %).
English: 100 ml solution in a transparent plastic (cycloolefinic polymer) bottle closed with a fluoro-polymer coated bromobutyl rubber stopper and an aluminium/polypropylene cap with a flip component.
Slovenian: 100 ml raztopine v prosojni plastični (iz cikloolefinskega polimera) steklenici, zaprti z zamaškom iz bromobutilne gume, prevlečeni s fluoropolimerom, in s pokrovčkom iz aluminija/polipropilena z zaporko.
English: If you are under dental treatment or are due to undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and tell your dentist that you are being treated with Aclasta.
Slovenian: Če ste v postopku zdravljenja zoba ali ste v kratkem dogovorjeni za zobozdravstveni kirurški poseg (na primer puljenje zoba), zdravnika obvestite o zdravljenju zob, zobozdravniku pa povejte, da prejemate zdravilo Aclasta.
English: After initiation of the zoledronic acid infusion, plasma concentrations of the active substance increased rapidly, achieving their peak at the end of the infusion period, followed by a rapid decline to < 10% of peak after 4 hours and < 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak levels.
Slovenian: Po začetku infundiranja zoledronske kisline so se koncentracije zdravilne učinkovine v plazmi hitro zvišale, dosegle ob koncu infundiranja vrh, ki mu je sledilo hitro znižanje na <10 % najvišje dosežene koncentracije po 4 urah in na <1 % najvišje dosežene koncentracije po 24 urah, čemur je sledilo dolgotrajno obdobje zelo nizkih koncentracij, ki niso presegle 0,1 % najvišje koncentracije.
English: In another study in men (study CZOL446M2308) an annual infusion of Aclasta was non-inferior to weekly alendronate for the percentage change in lumbar spine BMD at month 24 relative to baseline.
Slovenian: V drugi študiji z moškimi (študija CZOL446M2308) letna infuzija zdravila Aclasta ni bila slabša od tedenske uporabe alendronata glede odstotka spremembe mineralne gostote kosti ledvene hrbtenice po 24 mesecih v primerjavi z izhodiščem.
English: While being treated with Aclasta, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.
Slovenian: V času zdravljenja z zdravilom Aclasta morate skrbeti za dobro ustno higieno (kar vključuje redno čiščenje zob) in redno hoditi na rutinske preglede k zobozdravniku.
English: Aclasta is also used in patients who have recently broken their hip in a minor trauma such as a fall and therefore are at risk of subsequent bone breaks.
Slovenian: Zdravilo Aclasta uporabljamo tudi pri bolnikih, ki so si pred kratkim zlomili kolk ob lažji poškodbi, na primer pri padcu, in je zato tveganje za nadaljnje zlome pri njih povečano.
English: Before receiving Aclasta treatment, tell your doctor, pharmacist or nurse if - you have any problems with your mouth or teeth such as poor dental health, gum disease, or a planned tooth extraction; - you do not receive routine dental care or have not had a dental check-up for a long time; - you are a smoker (as this may increase the risk of dental problems); - you have previously been treated with a bisphosphonate (used to treat or prevent bone disorders); - you are taking medicines called corticosteroids (such as prednisolone or dexamethasone) - you have cancer.
Slovenian: Preden prejmete zdravilo Aclasta, povejte zdravniku, farmacevtu ali medicinski sestri, če: - imate težave v ustih oziroma z zobmi, kot so slabo zdravstveno stanje zob, bolezni dlesni ali načrtovana ekstrakcija (puljenje) zoba; - nimate urejene redne oskrbe zob oziroma že dolgo niste bili na zobozdravstvenem pregledu; - ste kadilec (saj to lahko povečuje tveganje za težave z zobmi); - ste že kdaj prej prejemali katerega od difosfonatov (ki jih uporabljamo za zdravljenje ali preprečevanje bolezni kosti); - prejemate zdravila, ki jih imenujemo kortikosteroidi (kot sta prednizolon ali deksametazon); - imate raka.
English: Aclasta must not be mixed or given intravenously with any other medicinal products.
Slovenian: Zdravila Aclasta ne smete mešati ali dajati intravensko skupaj z drugimi zdravili.
English: Six patients who achieved therapeutic response 6 months after treatment with Aclasta and later experienced disease relapse during the extended follow-up period were re-treated with Aclasta after a mean time of 6.5 years from initial treatment to re-treatment.
Slovenian: Šest bolnikov, pri katerih je prišlo do terapevtskega odziva 6 mesecev po zdravljenju z zdravilom Aclasta, kasneje v obdobju podaljšanega spremljanja pa do recidiva bolezni, je ponovno prejelo zdravilo Aclasta, pri čemer je interval med začetnim in ponovnim zdravljenjem v povprečju znašal 6,5 let.
English: Not known** Hypersensitivity reactions including rare cases of bronchospasm, urticaria and angioedema, and very rare cases of anaphylactic reaction/shock
Slovenian: preobčutljivostne reakcije, vključno z redkimi primeri bronhospazma, urtikarije in angioedema in z zelo redkimi primeri anafilaktične reakcije/šoka
English: Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t½ 0.24 and t½ 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t½ 146 hours.
Slovenian: Intravensko dana zoledronska kislina se odstranjuje iz telesa s trifaznim procesom: hitro dvofazno izginotje iz sistemskega krvnega obtoka z razpolovnima časoma t1/2 0,24 ure in t1/2 1,87 ure, ki mu sledi dolga faza izločanja s končnim razpolovnim časom izločanja t1/2 146 ur.